Urovant Sciences Ltd. UROV
Set alert
— — —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 531.75M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -3.09
- Beta
- 0.00
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 12, 2021
- 50-d avg
- 16.21
- 200-d avg
- 13.98
- 1y target
- 16.17
Key statistics
- Market cap
- 531.75M
- Trailing P/E
- 0.00
- Forward P/E
- -3.09
- Price / sales
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- 50-day average
- 16.21
- 200-day average
- 13.98
Analyst view
Consensus: hold
Hold
Price target (mean) 16.17
- Target (low)
- 16.00
- Target (mean)
- 16.17
- Target (high)
- 16.25
Ratings (0m) 3 3 buy · 0 hold · 0 sell
- Strong buy1
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 12, 2021
Expected Feb 12, 2021. Consensus EPS estimate 0.00.
Financials — quick view
UROV Revenue — quarterly 0
UROV Net income — quarterly -46.80M
UROV EPS — quarterly -1.46
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 12, 2021 | Dec 1, 2020 | -1.59 | — | — | — |
| Nov 2, 2020 | Sep 1, 2020 | -1.50 | — | — | — |
| Aug 13, 2020 | Jun 1, 2020 | -1.36 | — | — | — |
| Jun 18, 2020 | Mar 1, 2020 | -1.25 | — | — | — |
| Feb 13, 2020 | Dec 1, 2019 | -0.95 | — | — | — |
| Nov 5, 2019 | Sep 1, 2019 | -1.15 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 16, 2020 | JP Morgan | down | Overweight | Neutral |
| Nov 16, 2020 | HC Wainwright & Co. | down | Buy | Neutral |
| Nov 13, 2020 | Jefferies | down | Buy | Hold |
| Jun 19, 2020 | HC Wainwright & Co. | main | — | Buy |
| Dec 31, 2019 | H.C. Wainwright | main | — | Buy |
| Mar 15, 2019 | SunTrust Robinson Humphrey | init | — | Buy |
News
- Urovant's OAB Gene Therapy Shows Improvement In Symptoms Compared To Placebo
- Stocks That Hit 52-Week Highs On Wednesday
- SHAREHOLDER ALERT: Halper Sadeh LLP Investigates the Following Companies -UROV, INFO, WDR, CKH, EIGI
- Sumitovant Biopharma Announces Urovant Sciences Receives U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB)
- Urovant Sciences Announces U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB)
- UROVANT SCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Urovant Sciences - UROV
- SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Sale of Urovant Sciences Ltd. to Sumitovant Biopharma
- RM LAW Announces Investigation of Urovant Sciences Ltd.
- Urovant Sciences: Buyout Price Is Too Low
- SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Urovant Sciences Ltd. - UROV
Your note
Sign in to keep a note on UROV — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BANSAL AJAY | Officer | Stock Award(Grant) | Apr 30, 2020 | 138,659 |
| HAAG-MOLKENTELLER CORNELIA | Officer | Stock Award(Grant) | Apr 30, 2020 | 145,277 |
| HINDMAN JAMES M | Director | Stock Award(Grant) | Jul 20, 2020 | 9,000 |
| JOHNSTON WALT | Officer | Stock Award(Grant) | Jun 1, 2020 | 108,647 |
| KATKIN KEITH A | Officer and Director | Conversion of Exercise of derivative security | Feb 18, 2020 | 199,680 |
| KURSTJENS SEF P | Director | Stock Award(Grant) | Jul 20, 2020 | 21,480 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Perceptive Advisors Llc | 9.52% | 3,116,831 | 50.27M | Dec 30, 2020 |
| Beryl Capital Management LLC | 1.07% | 351,579 | 5.67M | Dec 30, 2020 |
| Vanguard Group, Inc. (The) | 1.04% | 341,426 | 5.51M | Dec 30, 2020 |
| Prelude Capital Management LLC | 0.75% | 247,148 | 3.99M | Dec 30, 2020 |
| Gabelli Funds, LLC | 0.74% | 241,227 | 3.89M | Dec 30, 2020 |
| Candriam Luxembourg S.C.A. | 0.51% | 167,787 | 2.71M | Dec 30, 2020 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.38% | 125,487 | 2.02M | Dec 30, 2020 |
| Trust for Advised Port-Infinity Q Diversified Alpha Fd | 0.29% | 94,687 | 1.52M | Nov 29, 2020 |
| Gabelli Healthcare & Wellness Trust | 0.23% | 75,000 | 1.21M | Dec 30, 2020 |
| Fidelity Extended Market Index Fund | 0.14% | 47,382 | 768.06K | Jan 30, 2021 |
| Fidelity NASDAQ Composite Index Fund | 0.09% | 30,677 | 497.27K | Jan 30, 2021 |
| Gabelli Global Small & Mid Cap Value Tr | 0.08% | 25,000 | 403.25K | Dec 30, 2020 |